Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Coty P. Ho

Oncology
1180 N Indian Canyon Dr, Ste E218, 
Palm Springs, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
1180 N Indian Canyon Dr, Ste E218, 
Palm Springs, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Coty Ho is an Oncologist in Palm Springs, California. Dr. Ho is rated as an Experienced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Breast Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in OK
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

1180 N Indian Canyon Dr, Ste E218, Palm Springs, CA 92262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 06, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

3 Total Publications

A Case Series of Rare Immune-Mediated Adverse Reactions at the New Mexico Veterans Affairs Medical Center.
A Case Series of Rare Immune-Mediated Adverse Reactions at the New Mexico Veterans Affairs Medical Center.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: November 29, 2023
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Constantin A. Dasanu
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Constantin A. Dasanu
Hematology Oncology | Hematology | Oncology

Eisenhower Medical Center

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (9.7 miles away)
760-340-3911
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Constantin Dasanu is a Hematologist Oncology specialist and a Hematologist in Rancho Mirage, California. Dr. Dasanu is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Neuroendocrine Tumor, Vitamin B12 Deficiency Anemia, Waldenstrom Macroglobulinemia, Melanoma, and Bone Marrow Aspiration.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Chung-tsen T. Hsueh
Hematology Oncology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Chung-tsen T. Hsueh
Hematology Oncology | Oncology

Faculty Physicians And Surgeons Of Llusm

81 Highland Springs Ave, 
Beaumont, CA 
 (23.7 miles away)
909-558-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chung-tsen Hsueh is a Hematologist Oncology specialist and an Oncologist in Beaumont, California. Dr. Hsueh is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Bone Tumor, Anal Cancer, Adult Soft Tissue Sarcoma, Pancreaticoduodenectomy, and Bone Marrow Aspiration.

Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Davood Vafai
Hematology Oncology | Oncology
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Davood Vafai
Hematology Oncology | Oncology

Eisenhower Medical Center

40075 Bob Hope Dr, Suite A, 
Rancho Mirage, CA 
 (9.7 miles away)
760-341-3688
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Davood Vafai is a Hematologist Oncology specialist and an Oncologist in Rancho Mirage, California. Dr. Vafai is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Lung Cancer, Anal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ho's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 51 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile